{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"094-388-662-786-115","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"094-388-662-786-115"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10776,"type":"PATENT","title":"University of Zurich - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3600,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8246,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
Search Applicants and Owners separately: \"Uni* Zurich\"; \"Univ* Zuerich\"; \"Univ* Zuer*\"; \"Zuer* Uni*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2413
(a) subjecting a sample obtained from a patient who is symptom-free but affected with or at risk of developing a disorder, or a patient with an unusually stable disease course to a specimen of pathologically altered cells or tissue of predetermined clinical characteristics; and
(b) identifying and optionally isolating a binding molecule which binds to said specimen but not to corresponding cells or tissues of a healthy subject."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said sample comprises a body fluid or a cell sample, preferably wherein:
(a) said body fluid is a cerebrospinal fluid, plasma or urine; and/or
(b) said sample comprises or is derived from B-cells or memory B-cells."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 or 2, wherein said binding molecule is an antibody."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 3, wherein said patient and subject, respectively, is a human."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 4, wherein said patient has been determined to be affected with a not yet manifested disorder or at risk to develop the disorder by the presence or absence of a surrogate marker, preferably wherein said surrogate marker is selected from the group consisting of old age, brain amyloid load, ApoE genotype, APP genotype, PS1 genotype, levels in body fluids of Abeta peptide, isoprostanes, Tau, and phospho-Tau."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 5, wherein said disorder is selected from the group consisting of neurological disorders, autoimmune disorders and tumors, preferably wherein said disorder is Alzheimer's disease."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the sample is obtained from a patient fulfilling the following criteria:
(i) being 65 years of age or older;
(ii) having full cognitive capacity and good health; and
(iii) having no clinical signs of dementia; or
(iv) having unusually slow rates of progression of disease despite the presence of an established clinical diagnosis of probable Alzheimer's disease."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of any one of claims 1 to 7 further comprising the steps of:
(i) purifying B cells or B memory cells from a sample which has been identified to contain binding molecules, e.g. antibodies which bind to said specimen but not to corresponding cells or tissue of a healthy subject;
(ii) obtaining the immunoglobulin gene repertoire for said antibodies from said B cells or B memory cells; and
(iii) using said repertoire to express said antibodies, preferably wherein step (ii) comprises the steps of:
(iv) obtaining mRNA from said B cells or memory B cells;
(v) obtaining cDNA from the mRNA of step (iv); and
(vi) using a primer extension reaction to amplify from said cDNA the fragments corresponding to the heavy chains (HC) and the kappa light chains (LC) of said antibodies."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A binding molecule obtainable by the method of any one of claims 1 to 13, which is capable of selectively recognizing a neoepitope of a disorder-associated protein, preferably wherein the binding molecule does not substantially recognize said protein in its non-disorder-associated form."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The binding molecule of claim 9, which is an antibody or an antigen binding fragment thereof, preferably wherein the antibody is a human antibody."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The binding molecule of claim 9 or 10, wherein said disorder is a neurological disorder, preferably wherein said disorder is a disorder of the brain."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The binding molecule of any one of claims 9 to 11, which is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab') fragment, a F(ab) fragment, and an F(ab')2 fragment."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["A polynucleotide encoding the binding molecule of any one of claims 9 to 12."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A vector comprising the polynucleotide of claim 13, optionally in combination with a polynucleotide of claim 13 that encodes the variable region of the other immunoglobulin chain of said antibody."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising a polynucleotide of claim 13 or a vector of claim 14."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method for preparing a disorder-associated protein specific binding molecule, an antibody or a binding fragment or immunoglobulin chain(s) thereof, said method comprising:
(a) culturing the cell of claim 15; and
(b) isolating said binding molecule, antibody or binding fragment or immunoglobulin chain(s) thereof from the culture."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A binding molecule, an antibody, an immunoglobulin chain or a binding fragment thereof encoded by a polynucleotide of claim 13 or obtainable by the method of claim 16."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The binding molecule, antibody or binding fragment of any one of claims 9 to 12 or 17, which is:
(a) detectably labeled, preferably wherein the detectable label is selected from the group consisting of an enzyme, a radioisotope, a fluorophore and a heavy metal; and/or
(b) which is attached to a drug."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A composition comprising the binding molecule, antibody or binding fragment of any one of claims 9 to 12, 17 or 18, the polynucleotide of claim 13, the vector of claim 14 or the cell of claim 15, wherein:
(a) the composition is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier, optionally further comprising an additional agent useful for treating Alzheimer's disease, selected from the group consisting of small organic molecules, anti-Abeta antibodies, and combinations thereof; or
(b) the composition is a diagnostic composition and further comprises reagents conventionally used in immuno or nucleic acid based diagnostic methods."],"number":19,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}